Fluvastatin alleviates doxorubicin-induced cardiac and renal toxicity in rats via regulation of oxidative stress, inflammation, and apoptosis associated genes expressions.

Autor: Kuşçu GC; Department of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Turkey., Gürel Ç; Department of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Turkey.; Department of Histology and Embryology, Faculty of Medicine, Harran University, Şanlıurfa, Turkey., Buhur A; Department of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Turkey., Karabay Yavaşoğlu NÜ; Department of Biology, Faculty of Science, Ege University, Izmir, Turkey., Köse T; Department of Biostatistics and Medical Informatics, Faculty of Medicine, Ege University, Izmir, Turkey., Yavaşoğlu A; Department of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Turkey., Oltulu F; Department of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Turkey.
Jazyk: angličtina
Zdroj: Drug and chemical toxicology [Drug Chem Toxicol] 2023 Mar; Vol. 46 (2), pp. 400-411. Date of Electronic Publication: 2022 Feb 24.
DOI: 10.1080/01480545.2022.2043351
Abstrakt: Doxorubicin (DOXO) is a cytostatic agent used in the chemotherapy protocol of several cancers for more than 40 years, but usage of this drug in cancer treatment has been limited due to severe renal and cardiac tissue toxicities that may result in death in patients. Fluvastatin (FV) is a fully synthetic hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor used as a cholesterol-lowering agent in patients with hypercholesterolemia. Previous studies revealed that FV also exhibits antioxidant, anti-inflammatory, and antitumor activity. Additionally, our previous study indicated that FV exerts a prophylactic effect on DOXO-induced testicular toxicity by preventing lipid peroxidation, supporting the antioxidant system, and regulating the blood-testis barrier-associated genes expression. Herein, we purposed to evaluate the possible therapeutic and the protective effects of FV on the DOXO-induced cardiac and renal toxicitiy model by histochemical, immunohistochemical, biochemical, and real-time polymerase chain reaction (real-time PCR) analyses. Results point out protective use of FV exerts a beneficial effect by repressing lipid peroxidation and by regulating the inducible nitric oxide synthase (iNOS), nitric oxide synthase endothelial (eNOS), nuclear factor kappa-B (NF-κB), and Caspase-3 (Casp3) protein and mRNA expressions, which play an important role in mediating DOXO-induced renal and cardiac toxicity mechanisms. In conclusion, FV may be a candidate agent for the prevention of renal and cardiac toxicities in cancer patients receiving DOXO chemotherapy.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje